Glioblastoma Targeted Treatment Option Maximization by WGS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-25

Study Completion Date

2025-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Disease Progression and Treatment-induced Alterations in Glioblastoma

NCT02152748

Brain Tumor

UNKNOWN

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

NCT03770468

Glioblastoma

COMPLETED

Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients

NCT04219475

Glioblastoma

SUSPENDED

NCT Neuro Master Match - N²M² (NOA-20)

NCT03158389

Glioblastoma, Adult

COMPLETED PHASE1/PHASE2

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

NCT00897663

Brain and Central Nervous System Tumors

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Glioblastoma (GBM), the most common primary brain tumor, is without exception lethal. Every year 1000 patients are diagnosed with this disease in the Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumors inevitably recur. Currently, there is no gold standard at time of recurrence and treatment options are limited. In a retrospective study in two Dutch neuro-oncology centers, the overall survival (OS) for patients with recurrent GBM receiving best supportive care was 3 months, while patients receiving systemic treatment (usually nitrosurea), radiation therapy or surgery followed by systemic treatment or radiotherapy had respectively 7.3 months, 9.2 months and 11 months OS. Unfortunately, the results of dedicated trials with new drugs have been very disappointing. For those to be meaningful, extensive molecular screening is needed.

The goal of the project is to obtain the evidence for changing standard of care procedures to include extensive molecular diagnostics and consequently adapt care guidelines for this specific patient group with very poor prognosis by offering optimal and timely benefit from novel therapies, even in the absence of traditional registration trials for this small volume cancer indication.

Objective: To determine the value of and generate the clinical evidence for routine application of Whole Genome Sequencing (WGS)-based diagnostics and targeted therapy guidance for glioblastoma patients at time of first recurrence.

Study design: Prospective diagnostic multicenter cohort study Study population: Adult glioblastoma patients with recurrent disease that are undergoing resection or debulking as part of their standard care and from whom written informed consent is obtained.

Intervention: A 10 mL blood sample will be drawn once to assess each patient's germline DNA background variation that will discriminate somatic mutations from the patient's germline DNA background variations. All other interventional procedures required to perform this study are part of standard procedures.

Main study parameters/endpoints:

Primary study endpoint: Overall survival

Secondary study endpoints:

* Tumor and blood collection success rate (target \>85% of all patients included)
* Number of successful WGS reports (reports for \>80% of patients for which tumor material was collected)
* Number of targeted treatment options identified (at least one potentially actionable DNA alteration in \>75% of patients with a WGS report)
* Number of experimental treatments available for GBM patients (relevant (off-label) drugs for at least 50% of the identified indications should be available through a study, including the Drug Rediscovery Protocol (DRUP)
* Thirty-two percent of patients starting a targeted treatment in presence of actionable variant (currently 16%)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

whole genome sequencing after standard of care resection at first relapse

Group Type EXPERIMENTAL

whole genome sequencing

Intervention Type DIAGNOSTIC_TEST

whole genome sequencing will be performed on tumor material after re-resection per standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

whole genome sequencing

whole genome sequencing will be performed on tumor material after re-resection per standard of care

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection;
2. Age ≥ 18 years;
3. Able and willing to give written informed consent;
4. Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity;
5. KPS performance status ≥70.

Exclusion Criteria

1. Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies);
2. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No